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Background: A robust estimate of the number of people with chronic hepatitis
C virus (HCV) infection is essential for an appropriate public health response and
for monitoring progress toward the WHO goal of eliminating viral hepatitis. Existing
HCV prevalence studies in the European Union (EU)/European Economic Area (EEA)
countries are heterogeneous and often of poor quality due to non-probability based
sampling methods, small sample sizes and lack of standardization, leading to poor
national representativeness. This project aimed to develop and pilot standardized
protocols for undertaking nationally representative HCV prevalence surveys in the general
adult population.
Methods: From 2016 to 2019 a team from the Robert Koch-Institute contracted
by the European Centre for Disease Prevention and Control synthesized evidence on
existing HCV prevalence surveys and survey methodology and drafted a protocol. The
methodological elements of the protocol were piloted and evaluated in Bulgaria, Finland
and Italy, and lessons learnt from the pilots were integrated in the final protocol. An
international multidisciplinary expert group was consulted regularly.
Results: The protocol includes three alternative study approaches: a stand-alone
survey; a “nested” survey within an existing health survey; and a retrospective testing
survey approach. A decision algorithm advising which approach to use was developed.
The protocol was piloted and finalized covering minimum and gold standards for all
steps to be implemented from sampling, data protection and ethical issues, recruitment,
specimen collection and laboratory testing options, staff training, data management
and analysis and budget considerations. Through piloting, the survey approaches were
effectively implemented to produce HCV prevalence estimates and the pilots highlighted
the strengths and limitations of each approach and key lessons learnt were used to
improve the protocol.
Sperle et al. Protocol for Hepatitis C Prevalence Surveys
Conclusions: An evidence-based protocol for undertaking HCV prevalence serosurveys
in the general population reflecting the different needs, resources and epidemiological
situations has been developed, effectively implemented and refined through piloting. This
technical guidance supports EU/EEA countries in their efforts to estimate their national
hepatitis C burden as part of monitoring progress toward the elimination targets.
Keywords: hepatitis C, HCV, general population, prevalence, technical protocol, surveys, questionnaires
BACKGROUND
The World Health Organization (WHO) has set ambitious
targets for the elimination of viral hepatitis as a public health
threat by 2030 in the global health sector strategy on viral
hepatitis 2016–2021 (1).
One of the five strategic directions outlined in the strategy
entails information for focused action, underlining the
importance of collecting robust data on the viral hepatitis
epidemic in order to improve and guide implementation of
efforts in the response. An update on the progress of the
implementation of the strategy was recently published by WHO,
stressing the need to strengthen and more regularly update viral
hepatitis data in order to improve implementation (2). Robust
estimates of the number of people with chronic hepatitis C virus
(HCV) infection are needed and its prevalence is one of 10 core
indicators (C.1.b), identified by the WHO in their framework on
monitoring and evaluation for viral hepatitis (3).
Data on newly diagnosed and notified cases of viral hepatitis
are collected through the surveillance systems, which are in
place for HCV in the majority of countries in the European
Union (EU). However, completeness of data is a major issue, and
reporting of data according to EU case definitions to enable a
clear comparison across countries and time remains challenging
(4, 5). Furthermore, the data collected through the surveillance
systems are largely influenced by the local testing strategies rather
than actual epidemiological trends or burden of disease.
HCV prevalence surveys provide key information on the
epidemiology of HCV infection. These surveys, in contrast
to surveillance data, provide a snapshot of the current
epidemiological situation, as all individuals in the sample infected
with HCV are identified, regardless of their diagnostic status.
However, a recent systematic review found that up-to-date
estimates of prevalence are lacking from many EU/European
Economic Area (EEA) countries (5, 6). This review also
found that studies that have been undertaken in the EU/EEA
are heterogeneous and often of poor quality due to non-
probability based sampling methods, small sample sizes and lack
of standardization leading to poor national representativeness
(5, 6).
The HCV epidemiology varies between countries and depends
on multiple factors. In countries with low prevalence, injecting
drug use (IDU) is an important risk factor and amain contributor
to the HCV epidemic (7). In these countries, people who
inject drugs (PWID) are often the group with the highest
prevalence and a key population to target with prevention and
treatment measures. In other countries, where higher levels of
transmission occurred in the past through unsafe injections, via
blood transfusions or other nosocomial transmission routes such
as unsafe use of glass syringes, as reported in Italy (8), HCV is
more widespread in the older general population (9). This type of
more generalized epidemics has been observed in some European
countries such as Czechia, Italy, Poland and Romania (10–14).
Knowing the HCV prevalence in the general population, and
standardizing the way data are collected and estimates generated
will contribute to more robust data allowing monitoring and
comparisons between countries and over time (15). This will
positively contribute to the monitoring and tracking of the
progress toward the WHO viral hepatitis elimination goal (3).
To address this issue and support EU/EEA Member States
(MS) in their efforts to generate robust estimates of HCV
prevalence, the European Center for Disease Prevention and
Control (ECDC) launched the “Sero-Prevalence Survey for
Hepatitis C in Europe” (SPHERE-C) project. The Robert Koch
Institute (RKI) was formally contracted by ECDC between 2016
and 2019 to develop a detailed technical protocol, with the aim
to develop and pilot standardized protocols for undertaking
nationally representative prevalence surveys of HCV in the
general adult population (15).
METHODS
A short inquiry was sent to all ECDC national focal points for
hepatitis in the EU/EEAMS in September 2016 to gain insight in
the countries’ availability of HCV prevalence data from previous
surveys and around future plans for undertaking work in this
area, as well as gauging interest in participating in a pilot of
the SPHERE-C protocol in 2018. Responses from 22MS were
obtained and used to guide the development of the protocol.
The development of the protocol was based on synthesis of
scientific information and evidence on HCV prevalence surveys.
A desktop review was conducted to define all the objectives
for the survey and to suggest methods for each objective. To
inform these objectives, a literature review was undertaken
to gain understanding of the local epidemiological gaps and
political needs. Thereafter, to identify the most appropriate
methods for the defined objectives, available information on the
methods used in previously conducted HCV prevalence surveys
was collected, and efforts were made to also identify surveys
outside the EU/EEA. The identified surveys and key information
were entered into a table, and study protocols were collected
through online searches or through contact with the researchers
who performed the surveys. Methodological criteria to achieve
minimum or gold standard for each objective was identified
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and a conceptual matrix presenting the findings was constructed
with areas covering selection of sites/population, sampling
and stratified sampling methods, specimen/data collection,
laboratory testing methods, storage and transport of samples,
confidentiality and ethical issues, data management, quality
control and training materials needed.
An expert group was set up to guide the direction of the
project and to provide feedback to the development of the
protocol. The expert group consisted of researchers, laboratory
experts, statisticians, medical doctors and epidemiologists from
across Europe and the USA. Three face-to-face consultations
were held with the expert group between 2016 and 2019. The
group was asked to comment on draft versions of the protocol
over the course of the project. The expert group agreed upon the
most relevant methodological approaches to be included in the
protocol based on the evidence presented by the RKI project team
and through consensus.
Three EU countries were selected to pilot the technical
protocol. Methodological elements in the protocol were piloted
to gather practical experience and evaluate its usability and
applicability. Lessons learnt were collected to guide the further
development of the protocol.
The following three pilots were carried out during 2018:
• A retrospective survey with testing of blood samples from the
FinHealth2017 national health examination survey in Finland
• A stand-alone survey in the city of Stara Zagora, Bulgaria
• A stand-alone survey in the city of Catanzaro, Italy
A pilot-specific study protocol based on the overall protocol and
study materials were developed for the pilot of the stand-alone
survey conducted in Stara Zagora, Bulgaria by the RKI. The local
survey teams in Finland and Italy developed their own pilot-
protocols and materials, based on the recommendations from
the technical SPHERE-C protocol. The aim for each of the three
surveys was formulated and tailored to the local context drawing
on the recommended aim in the technical protocol. All three
pilots were performed in close collaboration with the team at
RKI, and regular teleconferences were held with the local survey
teams to ensure that decisions made locally were coherent with
the technical protocol.
Indicators were developed to evaluate the feasibility of
the protocol and the methodological approaches. The
evaluation indicators were transformed into an evaluation
questionnaire with 10 main questions covering all sections in the
technical protocol including objectives of the survey, sampling
and sample frame, time spent, structure, coordination and
collaboration, ethical approval, data protection and informed
consent, awareness-raising, recruitment, personnel, budget,
data management and data collection (blood sampling and
questionnaire). The evaluation questionnaire was completed in
writing by the local survey teams in the three countries, and
then sent electronically to the RKI. Interviews to explore issues
in further depth were conducted with the local survey teams on
the phone with the survey teams from Finland and Italy, and
face to face during a 2 day evaluation workshop in December
2018, at the RKI in Berlin, Germany with the survey team
from Bulgaria.
RESULTS
The technical protocol provides background as well as
more detailed information demonstrating the importance
of undertaking prevalence surveys to generate robust estimates
of hepatitis C prevalence. Importantly, it provides options and
steps for planning and conducting a population-based hepatitis
C survey which can be adapted to the local context. The technical
protocol consists of two main parts:
1) Selection of a survey approach
2) Planning and conducting a survey
This is explained in detail in the published protocol (15), and in
brief below.
Three Survey Approaches
The technical protocol includes three survey approaches which
were identified as the best approaches through the desktop review
and through discussions with the expert group. The three survey
approaches are: a survey “nested” within an upcoming health
survey; a retrospective testing survey; and a stand-alone survey.
The three survey approaches all fulfill the pre-defined criteria
outlined in the protocol and are variations of a survey with
probability-based sampling. The protocol covers minimum
and gold standards for key aspects including: sampling; data
protection; ethical issues; recruitment; specimen collection;
laboratory testing; staff training; data management; quality
assurance and budget considerations (15). As an example, for the
type of specimen, theminimum requirement is dried blood spots,
and the gold standard is venous blood samples (15).
Mandatory requirements and methodological options for an
HCV prevalence survey (for all three survey approaches) are
illustrated in Figure 1 and described in more details in the
published protocol (15).
Nested Survey
The nested survey approach requires an upcoming larger
population-based health survey of the general population, e.g.,
a national health examination survey (HES). In this approach,
the prevalence survey is nested in this larger survey, which
makes it less resource intensive and costly due to the use of the
existing infrastructure of the already planned survey. This allows
additional testing of the participants for HCV, as well as collection
of HCV-related behavioral data, with little extra effort. Therefore,
this option requires relatively small amounts of financial and
human resources. The chances of a representative sample are
increased if the sample size calculations for the HES are sufficient
for the expected prevalence of HCV due to the often rigorous
sampling strategy and efforts to reduce non-response, that are
part of a larger population-based survey.
Retrospective Testing Survey
This approach requires a recently conducted population-based
survey. From stored blood samples of a former survey, HCV
testing can be performed retrospectively. The criterion of
probability-based sampling needs to be fulfilled. Furthermore,
it is important to ensure that there is a sufficient number of
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FIGURE 1 | Overview of mandatory requirements and methodological options for an HCV prevalence survey.
samples with enough material left for testing, and that these do
not represent a biased sub-set of the original samples collected.
Further, informed consent that was given by participants needs to
include storage of samples for further research and retrospective
testing. If the abovementioned requirements are fulfilled, extra
costs for this approach will mainly arise from the laboratory work
and analysis of the data.
Stand-Alone Survey
The third option is to embark on a stand-alone HCV prevalence
survey where the primary aim is to estimate the HCV
prevalence (by age and sex). This is the most staff- and
financial resource intensive approach, as all steps needed to do
a survey, including sampling, data protection and ethical issues,
recruitment, specimen collection and laboratory testing options,
staff training, data management and budget considerations, need
to be performed.
Selecting a Survey Approach
A decision algorithm was developed and included in the protocol
to guide MS through a careful decision making process when
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selecting the most suitable survey approach for their respective
setting and situation (Figure 2) (15).
If a large population-based survey is planned, where blood
samples are collected (e.g., a HES with a probability-based
sampling of the general population), it is suggested to nest
the HCV prevalence survey into this population survey. The
precondition is that the planned survey fulfills the minimum
criteria outlined in the protocol, e.g., has a sufficiently large
sample size and is representative of the populations of interest.
Including HCV testing in existing survey protocols involves steps
similar to those for designing a new survey, although some
steps may be simpler as they have already been done for the
original survey (such as ethical approval, sampling process, and
the recruitment strategy).
If no population-based survey is planned, but a former survey
such as aHES or another studywith a probability-based sample of
the general population was conducted recently and included the
collection of blood samples, an option is to test the sera left over
from this survey retrospectively. Again, the above mentioned
criteria need to be met to ensure the quality of the data generated.
Furthermore, proper sample storage should be assured to prevent
bias due to HCV RNA degradation.
If none of the two above options are available, then a
third option is to do a stand-alone survey, where the primary
purpose is to estimate the HCV prevalence. When conducting a
stand-alone survey, all the steps for undertaking a survey need
to be carefully planned and undertaken. Setting up a stand-
alone survey in the general population is time- and budget
intensive. Therefore, a preliminary first step is to test any
residual or routinely collected sera (e.g., from antenatal care
screening). If the prevalence in those samples is found to be
low (<1%), it is recommended that prevalence surveys in key
populations at higher risk of infection, e.g., among PWID should
be prioritized over a population-based survey in the general
population (Figure 2).
If none of the three survey approaches are possible there
are several alternative methods to consider, although these
methods may be more subject to potential bias. These include
testing residual sera from laboratory samples (16, 17), samples
from proxy populations of the general population such as
pregnant women (18) or first-time blood donors (6) or
general practitioner or health insurance registries as well
as linking information from multiple national registries and
applying various modeling techniques (19, 20). These and more
FIGURE 2 | Decision algorithm to select the most suitable survey approach when planning a prevalence survey for hepatitis C in the general population (15).
*Alternative options exist that might be explored by countries to get an idea of the HCV prevalence level in the general population, if they do not have data from a
recent population-based prevalence survey or plans for a future survey and few resources for a stand-alone survey (15).
Frontiers in Public Health | www.frontiersin.org 5 May 2021 | Volume 9 | Article 568524
Sperle et al. Protocol for Hepatitis C Prevalence Surveys
alternative methods are explained in further detail the technical
protocol (15).
Results From Piloting the Protocol
The three separate survey approaches were planned to be piloted
in three different EU countries. However, these plans were
subsequently adapted on account of the local situation in each of
these three sites, so that finally the stand-alone survey approach
was piloted in two countries and the retrospective testing
approach was piloted in the third country. Furthermore, due to
local circumstances the recommended steps in the protocol for
the different survey approaches were adapted to fit with what




The main objectives of this pilot were to estimate the prevalence
of chronic HCV infection, by sex and age group, in the adult
population in the city of Stara Zagora, Bulgaria and to test the
feasibility and proposed methodological approach in the draft
technical SPHERE-C protocol.
Italy
In Italy, the initial plan was to nest the HCV survey onto a
planned HES focused on salt consumption (CUORE1). However,
this needed to be adapted as the sample size in the CUORE
survey was too small. Therefore, the sample size was re-calculated
and the local team took the decision to undertake a stand-
alone survey.
The objectives of the survey pilot in Italy were to estimate
the age- and sex specific prevalence of chronic HCV infection,
age- and sex specific prevalence of exposure to HCV and
the prevalence of undiagnosed HCV in the adult population
of the city of Catanzaro, Southern Italy. All these objectives
were fulfilled.
Nested Survey Approach With
Retrospective Testing of Samples
Finland
The main objectives were to estimate the anti-HCV and
prevalence of chronic infection in the Finnish general population
(above 18 years of age) using the samples from the FinHealth2017
national health examination survey. A secondary objective was
to match the data with the national infectious disease register, in
order to generate an estimate of the undiagnosed fraction. The
objectives of the survey were fulfilled.
General Results
From the evaluation of the pilots and the technical protocol,
various challenges were reported by the local survey teams. In
Table 1 below, the sections included in the technical protocol
are listed together with key lessons learnt from the three pilot
surveys, and implications for the protocol. The detailed results
of the pilot in Bulgaria are published elsewhere (22).
1Available online at: http://www.cuore.iss.it/eng/factors/HES2018-2019.asp.
DISCUSSION
The survey approach selected to estimate HCV in the adult
general population needs to be carefully considered. Conducting
a population-based survey is challenging, resource intensive,
requires a good survey infrastructure, and a sufficient number
of well-trained staff members. Therefore, the preferred option
is to make use of an already planned population-based health
survey, or to make use of retrospective testing of already collected
samples, providing that requirements are fulfilled to ensure
representativeness. However, these approaches also have their
limitations, as, for example, nesting a survey onto a pre-planned
survey may not fit in with the scope or logistical capacity of the
pre-planned survey.
The evaluation of the three pilot surveys indicated that the
different survey approaches selected are suitable methodological
designs for estimating the anti-HCV and the chronic
HCV infection prevalence in the adult general population.
Nonetheless, the pilots were associated with several important
limitations. The stand-alone surveys were only conducted on
city level, and conducting these on national level is likely to
be more complex. The nested survey design outlined in the
protocol was not fully piloted, as the survey in Finland adapted
the approach and retrospectively tested the samples for HCV.
Nonetheless, methodological elements in the technical protocol
for conducting HCV prevalence surveys has been demonstrated
to be a useful and effective tool for EU/EEA MS as expressed
by the local survey teams in the qualitative evaluation (15).
Importantly, the protocol considers different situations in
different settings by assisting countries through careful decisions
that need to be made to select the most appropriate survey
approach for any given context.
The technical protocol refers to chronic HCV. Having an up to
date estimate of chronic HCV is particularly important given the
availability of the direct acting antiviral treatments (DAAs) for
HCV. It has been demonstrated that increased access to DAAs
leads to a decrease in HCV incidence and prevalence (23, 24).
Although low, monitoring the HCV burden and estimating the
number of people in need of treatment is of critical importance
in the response to viral hepatitis.
Lessons From the Pilots
Although the nested survey approach is the first approach to
consider, it is first and foremost critical that the minimum
requirements are fulfilled. This was not the case in the pilot in
Italy where the CUORE survey was not powered to estimate the
HCV prevalence. However, while it would have been possible
to nest onto the survey, and then sample additional people for
HCV testing to reach the sample size calculated for the HCV
prevalence survey, the Italian survey team decided to change
survey approach to a stand-alone approach. This approach
however required more efforts in terms of organization and time
as well as human and financial resources.
The original plan in Finland was a nested survey. However,
delay in getting access to the samples for HCV testing meant that
it ended up resembling more a retrospective testing approach.
Lessons from the retrospective testing of samples in Finland
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TABLE 1 | Summary of methodological details, results of the pilots, lessons learnt, and implications for the technical protocol (15).






Names and addresses of invitees
were not allowed to be shared
with study team, invitation letters
needed to be sent out by the
municipality holding the register
Required to call every participant
for scheduling appointment to
return test results
Data protection issues and
ethical approval conducted
previously by FinHealth study
team. Informed consent form
already included possibility of
testing for some other diseases
Plan for getting the ethical
approval early to be able to still
adjust according to requested
changes
Data collection and processing
according to the General Data
Protection Regulation (GDPR) in
the EU 2016/679 required,
therefore early contact with the
national data protection
agency advised
Sampling method Simple random sample stratified
by age and sex
Simple random sample stratified
by age and sex
Two-stage cluster sampling
stratified by age and sex
Sample should be selected using
a probability-based random
sampling method
For smaller geographical areas
(e.g., cities) simple random
sampling may be applied
Sampling frame Local population register of the
city of Stara Zagora
Local population register of the
city of Catanzaro
National population register Population registers should be
up to date
Sample size calculation N = 999 (expected prevalence of
chronic HCV was 1.0% and a
lower precision bound of 0.25%)
N = 889 (expected prevalence of
of chronic HCV infection of 1.0%
for age group 35–65 (upper
precision bound 2.2%) and 5.0%
for age group 65+ (upper
precision bound 10.0%)
N = 10,305 (expected
prevalence of current HCV
infection (anti-HCV and HCV
RNA positive) of 1% and a lower
precision bound of 0.25%)
Ensure large enough sample size
to get a valid estimate [Input and
statistical formula on how to
calculate sample size included in
technical protocol (15)]
Recruitment strategy Tracked invitation letter.
Reminders: a second tracked
invitation letter
One invitation letter (in 4 rounds).
For each round a new subset of
the sample was invited
First contact with a postcard,
followed by an invitation letter.
Reminders: postcards, phone
calls, SMS reminders
Emphasize that more recruitment
efforts are needed to ensure a
high enough response rate and
to include the “hard to reach”
populations who may have a
poorer health
Only tracked letters are not
recommended
Make at least three attempts to
reach participant (invitation letter,
reminder letter, phone call, SMS
reminders, or house visits)
Include a pre-test to test the
effectiveness of
different incentives
Promotion of the survey Information leaflet for invitees;
contact with and engagement of
local authorities; local media
campaign to inform about
hepatitis C and encourage
participation in the survey
including information posters in
local pharmacies and outpatient
care facilities (general
practitioners and medical
centers); 3 local press
conferences, local radio and
television broadcasts
Information leaflet for invitees;
contact with and engagement of
local authorities; awareness
posters for the survey displayed
in waiting rooms of general
practitioner practices and in the
hospital of Catanzaro
Information leaflet for invitees;
contact with and engagement of
local authorities; Press
conference, newspaper articles,
radio and television broadcasts
Information leaflet (and website)
to inform invitees are strongly
recommended for all surveys
Information and promotion of the
survey among the general
population through media and
local authorities, and among
health care staff
are recommended
Data collection period 10 weeks (5 September
2018–16 November 2018)
4 rounds of 1 week each in a
period of 7 months
(June 2018–December 2018)
7 months (January 2017–July
2017)
Plan extendible data collection
period/buffer of time in case
sample size was not reached in
the planned period. The data
collection period in Bulgaria
should have been prolonged to
reach sample size
(Continued)
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TABLE 1 | Continued




People invited 1,998 (1,166 picked up their
letter)
9,000 (8,655 letters delivered) 10,247 Take into account expected
non-response rate, and consider
that the non-response rate may
be higher than 50%
Participants 252 1,003 5,923 available samples tested
Incentives A coffee mug and a pencil One day off from work for
participants
Results of the health
examinations and laboratory
analysis of the collected
biological samples
Consider different incentives for
different age-groups.
Include a pre-test to test the
effectiveness of
different incentives
Response rate 12.6% Net response rate: 21.6%
(of those who got the invitation)
11.1% Net response rate: 11.6%
(of those who got the invitation)
Overall response rate for
questionnaire: 59.6%
Net response rate for health
examination: 57.8%.
Low response rates in all pilots
highlight the challenge of
reaching the target set by EHES
of 70% (15, 21) and





including questions specific to
HCV
Migrants were not sufficiently
included, and therefore unknown
if translation was needed
Self-administered questionnaire
including questions specific to
HCV
Migrants were not sufficiently
included, and therefore unknown
if translation was needed
Self-administered questionnaire
completed before HES either
electronically or manually
No HCV-specific questions (e.g.,
HCV infection risks) included
Self-administered questionnaires
work well in general populations
Prior to data collection, assess
whether translation /interviews
are needed
In nested surveys, early
collaboration with survey team
important to ensure that
HCV-related questions
are included
Laboratory Local laboratory for serology and
one in capital for confirmatory
testing and PCR. Shipping by
using routine procedures




shipping of samples to another
laboratory for serology and PCR
Centralized testing of all steps in
one laboratory is recommended
Alternatively two-step test
algorithm in two laboratories
when routine shipping
procedures can be used
In retrospective design, samples
for HCV testing should be
aliquoted during data collection
Testing algorithm Anti HCV ELISA, followed by
PCR. Immunoblot for PCR
negative samples
Anti HCV ELISA, followed by
PCR. Immunoblot for PCR
negative samples
Anti HCV ELISA, followed by
Immunoblot (HCV ELISA
positives and borderlines) and
PCR (Immunoblot positives and
borderlines)
The number of false positives
may be high in low prevalence
settings, therefore confirmation
of anti-HCV reactive, PCR





Test results were returned to all
survey participants, who received
a letter with their participant ID
and a date for when they would
receive their test result in person
at the Regional Health
Inspectorate. Those who were
tested positive were linked to
specialised medical care
All participants contacted via
phone to schedule an
appointment during which they
would receive their test result
Those who were tested positive
were linked to specialised
medical care
Positive cases were contacted
by phone and a letter. Those who
were tested positive were linked
to specialised medical care
Plan enough time, staff and
budget to have appointments
with all participants or outsource
the scheduling of appointments
Alternatively only inform
positive-tested about test results
Returning test results from
retrospective testing only if data






were calculated for categorical
variables (participants and
non-participants). For the chronic
HCV prevalence weighting





non-responders with regard to
their sex, age distribution and
housing deprivation level. Crude,
age and sex specific,
Post-stratification weights were
used to correct the possible for
non-response biases by
incorporating population
distributions of sex, age and
other appropriate characteristics
into survey estimates
95% confidence intervals (taking
into account the design of the
survey)
Weighting should take into
account at least age and sex, if
possible, further characteristics
(e.g., regional or urban–rural
(Continued)
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calculated as crude estimates
and weighted estimates with
95% Confidence Intervals




calculated. The associations of
HCV infection with the different
predictor variables were
investigated by log binomial
regressions with sampling
weights or by exact logistic
regressions as appropriate.
Variables with a p < 0.20 at the
univariate analysis were
considered as potential
predictors and included in
multivariable analysis
All analyzes were carried out in
Stata 15.1
Design based weighted overall
and age- and sex-stratified
estimates of the HCV prevalence
and their 95% confidence
intervals were calculated




regression model with sampling
weights. Predictive margins of
interests were calculated
distribution, migration status)
95% confidence intervals (taking
into account the design of the
survey)
Weighting should take into
account at least age and sex, if
possible, further characteristics
(e.g., regional or urban–rural
distribution, migration status)
Budget implications Most time and resources spent
on administrative challenges
Most resources spent on
sending letters and scheduling
appointments
Most time spent on preparing
samples for testing





underlined the importance of communication and mutual
understanding between the two teams (main survey team and
HCV prevalence survey team) in order to keep the timeline
for the HES and ensure the testing of samples for HCV. Early
and clear communications may also increase the chances of
including extra HCV relevant questions in the questionnaire. For
the survey in Finland, questions on past or present drug use were
not included to keep the questionnaire short. It is important
to be able to standardize results across Europe, and therefore
important to collect a minimum set of sociodemographic data
for each participant, regardless of survey approach. These include
information on sex,) at the time of blood sample collection,
and a postal or geographical code. The core set of data, as
well as recommended questions on HCV testing and status
and risk factors, are provided in the technical protocol (15).
There are various strengths using the nested approach, but
also important limitations. While a significant advantage is the
possibility to make use of an established survey including its
sampling approach and the associated socio-economic data,
the disadvantage is that there may be limited opportunities to
influence the sampling strategy and the overall schedule of the
survey, which was a barrier for the Finnish pilot.
Another challenge with the nested approach is interest from
different research groups with focus on different disease areas.
With a probability-based sampling and rigorous recruitment
strategy, the samples are considered of high value and can
contribute to valuable knowledge for several disease areas.
There are often competing proposals and research ideas from
different groups, all wanting to include specific questions in the
questionnaire, making early planning and prioritization crucial.
In the retrospective testing approach in Finland, more time
was needed for sample handling. Therefore, the Finnish team
recommends to draw specific samples for infectious diseases
testing during the HES, as opposed to only one blood sample
which then needs to be tested by multiple groups.
It was not possible to pilot all recruitment steps recommended
in the technical protocol (letter, phone calls, short message
service (SMS) reminders, and house visits). In Italy, only letters
were sent in several rounds, and for each round, a new subset
of the sample was invited to participate. While the sample
size was reached, the recruitment strategy implemented for the
Italian survey may have led to a less representative sample
as those who take part after one recruitment attempt are
easier to reach and thereby likely in better health or more
interested or have more time. Additional recruitment steps are
needed to reach initial non-responders, who might differ in
socioeconomic and other characteristics from those who more
easily accept to participate (25–27). Other innovative approaches
may help to increase the number of respondents, e.g., by self-
sampling or by offering telephone interview (28, 29). Similarly,
the low response rate in Bulgaria is likely to have been caused
by the change in recruitment strategy which only allowed
invitation via letter. Further recruitment steps are needed to
ensure a higher response rate such as e.g., phone calls and
house visits (27, 30), which could not be piloted. In Finland,
SMS reminders have previously proved successful in increasing
participation among young invitees (30). Implementing several
recruitment steps, as outlined in the SPHERE-C protocol, is
important to ensure a high response rate. If unable to implement
enough steps to ensure a high response rate, the large efforts
needed to conduct a stand-alone survey may be unwarranted
as the end sample will not be representative. In which case,
Frontiers in Public Health | www.frontiersin.org 9 May 2021 | Volume 9 | Article 568524
Sperle et al. Protocol for Hepatitis C Prevalence Surveys
a better choice may be an alternative approach for estimating
HCV prevalence.
The impact of incentives depends on the context in which
they are offered. While the incentive provided in Stara Zagora
was well-received (22), different incentives tailored to different
age groups may have resulted in a greater response rate. For all
surveys, themost efficient incentives and recruitment efforts need
to be locally evaluated, e.g., through a pre-test prior to the survey,
and decided upon according to context (26).
It may be that neither of the recommended three approaches
are an option for some countries. Therefore, if there are no
resources available for a stand-alone survey and testing stored
samples or samples from a planned survey is not possible,
alternatives may be explored. These may include testing residual
sera from clinical laboratories, looking at data from first-time
blood donors or looking at data from routine screening of
pregnant women (15). These possibilities may also be used to
get an idea of what the prevalence is before embarking on a
stand-alone HCV prevalence survey. Even if such alternative
approaches are likely to be based on non-probability-based
sampling which increases the risk of bias, they may provide
sufficient evidence for focusing future prevalence surveys in at-
risk populations. By testing residual sera from different groups,
bias can be reduced (16). It is of crucial importance that
regardless of approach and method selected, efforts are made to
ensure that the minimum requirements outlined in the technical
protocol are met to ensure that results are representative and
useful for estimating the HCV prevalence.
If a country sets out to do a stand-alone survey, it is highly
advisable to include testing for other infectious diseases, such as
hepatitis A, B, D, E, HIV, other sexually transmitted infections, in
addition to HCV. It may also be relevant, depending on country
and context, to consider including vaccine preventable diseases
or relevant non-communicable diseases. A lot of work needs
to be put into the planning and conducting of a stand-alone
prevalence survey, especially if recommended approaches are
taken to ensure a good response rate, and therefore it will make
sense to make use of the rigorous sampling strategy to test for
other infectious diseases.
Moving From HCV Prevalence Estimate in
General Population to National Prevalence
Estimate
Estimating the HCV prevalence in the general population is only
one part of getting a national estimate of the HCV prevalence,
which is one of the WHO core indicators in the monitoring and
evaluation framework (3).
More data and additional methodological approaches are
needed in order to generate a national prevalence estimate.
Some countries have combined data from multiple registers and
applied various modeling techniques to generate national HCV
prevalence estimates (20, 31). Others have applied the workbook
method (32) or the Bayesian multi-parameter evidence synthesis
(MPES) (33). For these approaches, additional activities beyond
what is covered in the technical protocol are needed. These
activities include identifying the at-risk groups for HCV, which
include PWID (both current and former), prison population,
men who have sex with men (MSM) and migrants (documented
and undocumented), then estimating the sizes and the prevalence
in these groups. It is important to consider thatmany populations
are not sufficiently captured in general population surveys
but may contribute considerably to the total burden of HCV.
Modeling studies from the UK and the USA suggest that the
majority of people living with chronic HCV are either current
or former PWID—with so-called “never injectors” contributing
much less to the total burden of HCV (estimates from the
UK suggest only around 15%) (31, 33–36). However, the
epidemiology varies across Europe, with iatrogenic transmission
an important driver of infection in some countries and non-
PWID groups, such as migrants and MSM, affected in other
countries (5, 37).
In conclusion, an evidence-based technical protocol for
undertaking HCV prevalence surveys in the general population
reflecting the different needs, resources and epidemiological
situations across Europe has been developed and found
useful through piloting (15). This technical protocol will help
support EU/EEA countries in estimating their national viral
hepatitis burden.
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